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Background: Glucocorticoids, secreted by the adrenals in response to stress, profoundly affect structure and
plasticity of neurons. Glucocorticoid action in neurons is mediated by glucocorticoid receptors (GR) that operate as
transcription factors in the regulation of gene expression and either bind directly to genomic glucocorticoid
response elements (GREs) or indirectly to the genome via interactions with bound transcription factors. These two
modes of action, respectively called transactivation and transrepression, result in the regulation of a wide variety of
genes important for neuronal function. The objective of the present study was to identify genome-wide
glucocorticoid receptor binding sites in neuronal PC12 cells using Chromatin ImmunoPrecipitation combined with
next generation sequencing (ChIP-Seq).
Results: In total we identified 1183 genomic binding sites of GR, the majority of which were novel and not
identified in other ChIP-Seq studies on GR binding. More than half (58%) of the binding sites contained a GRE. The
remaining 42% of the GBS did not harbour a GRE and therefore likely bind GR via an intermediate transcription
factor tethering GR to the DNA. While the GRE-containing binding sites were more often located nearby genes
involved in general cell functions and processes such as apoptosis, cell motion, protein dimerization activity and
vasculature development, the binding sites without a GRE were located nearby genes with a clear role in neuronal
processes such as neuron projection morphogenesis, neuron projection regeneration, synaptic transmission and
catecholamine biosynthetic process. A closer look at the sequence of the GR binding sites revealed the presence of
several motifs for transcription factors that are highly divergent from those previously linked to GR-signaling,
including Gabpa, Prrx2, Zfp281, Gata1 and Zbtb3. These transcription factors may represent novel crosstalk partners
of GR in a neuronal context.
Conclusions: Here we present the first genome-wide inventory of GR-binding sites in a neuronal context. These
results provide an exciting first global view into neuronal GR targets and the neuron-specific modes of GR action
and potentially contributes to our understanding of glucocorticoid action in the brain.
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The brain is a major target of glucocorticoids (GCs) that
are secreted by the hypothalamus-pituitary-adrenal axis
in response to stress. In the brain there are two recep-
tors for glucocorticoids, the mineralocorticoid receptor
(MR) and the glucocorticoid receptor (GR), that differ in
their expression pattern and affinity for GCs. GR is* Correspondence: N.A.Datson@lumc.nl
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reproduction in any medium, provided the orabundantly expressed throughout the brain both in
neurons and non-neuronal cells such as microglia and
astrocytes [1-4]. GR has a relatively low affinity for its lig-
and, cortisol in humans and corticosterone in rodents
(both abbreviated as CORT), and is activated when
CORT levels rise, for example during stress. Upon CORT
binding, GR migrates from the cytoplasm to the nucleus
where it is involved in the regulation of gene
transcription.
Transcriptional regulation by GR is complex and sev-
eral molecular mechanisms have been described involving
both homodimers and monomers of GR. Direct bindingl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(GREs) in the vicinity of target genes, a process known as
transactivation, is the classical mode of action which
generally results in a potentiation of transcription [5].
However, GR also exhibits extensive crosstalk with other
transcription factors (TFs), and besides simple GREs
composite sites exist that contain a binding site for an-
other TF in close proximity to the GRE, resulting in either
a synergistic activation or a repression of transcription
[6,7]. Furthermore, GR monomers can also exert effects
on gene transcription by indirectly binding to the DNA
via an intermediate DNA-bound TF in so called tethering
response elements [8], mostly resulting in a repression of
transcription of the associated gene, a process referred
to as transrepression. This extensive crosstalk of GR
with other TFs not only vastly expands the range of
GR-control on physiological processes compared to the
classical GRE-driven transcriptional control in simple
GREs, but it also underlies the highly context-dependent
action of GCs.
Several TFs have been described that participate in
this crosstalk with GR, including Oct1, Ets1, AP-1 and
CREB at composite GREs and NF-κB, AP-1, CREB,
Oct-1/2, STAT6, SMAD3,4 and PU.1/Spi-1 at tethering
sites [6,7,9-16]. However, most of these crosstalk part-
ners of GR have been identified in studies on the im-
munosuppressive and the tumor suppressor properties
of GR [17-19], while very little is known about cross-
talk partners in a neuronal context.
In neuronal cells GR regulates the expression of a wide
diversity of genes involved in general cellular processes
such as energy metabolism, cell cycle and response to
oxidative stress, but also clearly is involved in regulating
a wide variety of genes important for neuronal structure
and plasticity [20]. Despite the fact that many neuronal
GC-responsive genes have been identified [21-23], it
remains unclear whether these genes are primary or
downstream targets of GR. The onset of high-throughput
sequencing combined with chromatin immunoprecipita-
tion (ChIP-Seq) has made it possible to characterize
genome-wide binding sites of TFs and today several stud-
ies have used this approach to identify global primary
GR-targets in a variety of cell types, including human
lung carcinoma cells (A549), mouse adipocytes (3T3-L1),
premalignant breast epithelial cells (MCF10A-Myc),
murine mammary epithelial cells (3134) and pituitary
(AtT-20) cells [24-27]. These studies have yielded an un-
precedented insight into genome wide GR targets as well
as molecular mechanisms of GR-signaling, but perhaps
one of the most striking findings is the low degree of
overlap in GR binding sites when comparing different
cell types, indicating that GR occupancy is highly cell
type specific [25]. Therefore, in order to gain insight into
global GR primary target in neurons, it is essential tocharacterize GR binding in a neuronal context. So far no
studies have taken a ChiP-Seq approach to characterize
GR-binding in a neuronal context.
The aim of the current study was to analyze genome-
wide GR-binding sites (GBS) in rat neuronal PC12 cells
using ChIP-Seq. The PC12 cell line is derived from a
pheochromocytoma of the rat adrenal medulla and can
be differentiated into a neuronal phenotype by stimula-
tion with nerve growth factor [28]. NGF- treated PC12
cells stop dividing, develop neurites, display electrical
activity and develop many other properties similar to
those of sympathetic neurons [28,29]. They are consid-
ered a useful model system for neurosecretion and neur-
onal differentiation [30] and have been extensively used
to study neuronal function in relation to GCs [31-33]. In
this study, besides identifying the binding sites of GR in
neuronal PC12 cells, we analysed which genes were
located in the vicinity of the binding sites, which gene
ontology classes were overrepresented, whether GR-
binding resulted in regulation of gene expression of
nearby genes and the motif composition of the binding
sites.
Results
Identification and genomic distribution of GR binding
sites in PC12 cells
ChIP-Seq resulted in the identification of 2,252 genomic
regions that were bound by GR after 90 minutes of con-
tinuous DEX-stimulation of neuronal PC12 cells. Of this
list, 1,183 regions had a p-value <0.05 and were consid-
ered to be significant and were used for further analysis.
An example of the ChIP-Seq data showing GR-binding
upstream of the tyrosine hydroxylase gene (Th) is shown
in Figure 1. To get insight into the genomic distribution
of GR binding, the shortest distance of the center of
each significant GBS to the nearest gene was determined
within a 100 kb region. Approximately one third (31%)
of all significant GBS was located within a gene, while
47% did not overlap with a gene but were located within
a 100 kb distance upstream or downstream of a gene
(Figure 2A). The remaining 22% of GBS were located
further than 100 kb upstream or downstream from the
closest gene. In total there were more GBS located up-
stream to genes than downstream: 38% vs 31%
respectively.
Based on their genetic location, the intragenic GBS
were subdivided into the following groups: 5’UTR and
3’UTR (including introns and exons that are located
there), introns, exons and GBS overlapping an exon/in-
tron junction (Figure 2B). The majority (79%) of intra-
genically located GBS were confined to intronic regions.
Only 16% of the intragenic GBS were located within the
5’UTR, upstream of the coding sequence of the gene, a
region classically considered to be involved in regulation
DEX 
VEH 
1 2 3 
Figure 1 Genomic distribution of Glucocorticoid Receptor binding sites (GBS) upstream of the Tyrosine Hydroxylase gene (TH). Two
significant peaks representing GR-binding are observed at approximately 5.7 kb (peak 1) and 19.7 kb (peak 3) upstream of the transcription start
site (TSS) as indicated by arrows. The 5.7 kb GBS was previously described in PC12 cells transfected with the TH promoter [34]. A third peak (peak
2) upstream of the TH gene was apparent, but was not significantly above background (IgG signal) at this position, so was not further analysed.
Data was visualized with the UCSC genome browser [35].
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regions containing GBS and the most nearby gene is
shown in Table 1. The full list of 1,183 GBS is available
in the additional material (Additional file 1: Table S1).
Reliability of ChIP-Seq data
To assess the reliability of the ChIP-seq data and the
stringency of the applied statistical threshold, ChIP-
qPCR experiments were performed in a new isolate of









Figure 2 Genomic distribution of GBS relative to nearby genes. A The
range from the nearest gene are indicated, showing that the number of G
subdivided into subregions: 5’UTR (exon or intron), intron, exon, intron/exowide range of p-values (from 1E-6 to 0.03). The selection
included five significant regions previously identified in
other studies, in the vicinity of Ddit4, Per1, Tle3,
FRMD8 and Ddc, which were also identified in the
current study and served as positive controls [26,27]
Figure 3A, B: grey bars). In addition, 12 novel GBS iden-
tified in this study in neuronal PC12 cells were selected
for validation (Figure 3A: black bars). All but one GBS
(Ccdc99) were successfully validated, showing that the






percentage of GBS that are present intragenically or within a certain
BS located within a gene is highest. B Intragenic GBS can be further
n overlap and 3’UTR regions.
Table 1 Top 50 of significance GR-binding sites
Region Chr Start End p-value Nearest TS (bp) Gene symbol Gene description
1 chr14 92730207 92730300 0 58382 ddc dopa decarboxylase
2 chr12 4225730 4225800 0 41349 N4BP2L2 NEDD4 binding protein 2-like 2
3 chr8 84942839 84942945 6.66E-16 −40027 FILIP1 filamin A interacting protein 1
4 chr3 159002303 159002377 3.44E-15 −68132 ptpn1 protein tyrosine phosphate,
non-receptor type 1
5 chr1 170271212 170271308 1.07E-14 38820 PARVA parvin, alpha
6 chr20 44499841 44499940 1.25E-14 −27572 CDC2L6 cell division cycle 2-like 6(CDK8-like)
7 chr1 208485510 208485587 2.67E-14 24399 FRMD8 FERM domain containing 8
8 chr10 55856373 55856471 1.24E-13 −3428 Per1 period homolog 1
9 chr10 95336367 95336493 1.82E-13 −1827 CYB561 cytochrome b-561
10 chr9 82139844 82139973 2.12E-13 −22571 AGFG1 ArfGAP with FG repeats 1
11 chr2 214126583 214126707 5.58E-13 119898 snx7 sorting nexin 7
12 chr7 71292501 71292588 1.31E-12 452930 Cohh1 Cohen syndrome homolog 1
13 chr10 108442435 108442545 1.13E-11 10507 Clqtnf1 C10q and tumor necrosis factor
related protein 1
14 chr1 14981944 14982032 2.76E-11 16334 il20ra interlukin 20 receptor, alpha
15 chr10 69940043 69940119 1.777E-10 250224 ACCN1 amiloride-sensitive cation
channel 1, neuronal
16 chr4 26732111 26732175 1.87E-10 −20533 cyp51 cytochrome P450, subfamily 51
17 chr1 203191165 203191336 2.39E-10 −19745 TH tyrosine hydroxylase
18 chr3 159218917 159219016 2.51E-10 −11706 Pard6b pa-6 (partitioning defective 6) homolog beta
19 chr3 11220641 11220714 2.76E-10 11081 PPAPDC3 phosphatidic acid phosphatase
type 2 domain containing 3
20 chr13 98085339 98085424 8.73E-10 −40128 srp9 signal recognition particle 9
21 chr10 16132564 16132677 1.10E-09 −105921 LOC685957 cytoplasmic polyadenylation element binding
protein 4
22 chr1 128794365 128794456 2.01E-09 −74086 CHD2 chromo domain helicase DNA binding protein 2
23 chr1 148370534 148370610 2.72E-09 483095 Dlg2 discs, large homolog 2
24 chr14 99179170 99179253 3.03E-09 −356843 etaa1 Ewing tumor-associated antigen 1; similar
to ETAA16 protein
25 chr3 120538726 120538946 4.16E-09 -32899 CHGB chromogranin B
26 chr16 36611065 36611165 5.78E-09 −285078 HAND2 heart and neural crest derivatives expressed 2
27 chr13 100632670 100632774 6.77E-09 58963 hlx H2.0-like homeobox
28 chr1 83486283 83486376 8.07E-09 2797 ZFP36 zinc finger protein 36
29 chr2 242852558 242852668 1.23E-08 50854 sh3glb1 SH3-domain GRB2-like endophilin B1
30 chr19 36308488 36308565 1.45E-08 36674 Zfp90 zinc finger protein 90
31 chr2 218383549 218383633 1.75E-08 12542 F3 coagulation factor III (thromboplastin,
tissue factor)
32 chr 72391772 72391896 2.24E-08 −85708 YWHAZ tyrosine 3-monooxygenase/tryptophan
5-monooxygenase activation protein,
zeta polypeptide
33 chr10 63291887 6321961 2.45E-08 −26356 rph3al rabphilin 3A-like (without C2 domains)
34 CHR1 203177190 203177316 3.19E-08 −5747 TH tyrosine hydroxylase
35 chr8 121454771 121454890 4.05E-08 −35296 Snrk SNF related kinase
36 chr17 7534539 7534637 4.25E-08 90348 Npepo aminopeptidase O
37 chr7 45295426 45295501 4.78E-08 155311 PPFIA2 protein tyrosine phosphatase, receptor
type, f polypeptide (PTPRF), interacting
protein (liprin), alpha
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Table 1 Top 50 of significance GR-binding sites (Continued)
38 chr10 19716893 19717068 6.83E-08 −7100 ccdc99 coiled-coil domain containing 99
39 chr1 179785291 179785400 7.20E-08 17710 Polr3e polymerase (RNA) III (DNA directed)
polypeptide E (80kd)
40 chr13 85831724 85831796 7.86E-08 14876 DDR2 discoid in domain receptor tyrosine kinase 2
41 chr2 240315238 240315326 8.89E-08 −18368 PDLIM5 PDZ and LIM domain 5
42 chr3 155445628 155445734 1.01E-07 −503522 Sdc4 syndecan 4
43 chr16 22356139 22356299 1.05E-07 19144 SLC18A1 solute carrier family 18 (vesicular monoamine),
member 1
44 chr10 75271499 75271582 1.65E-07 −112174 LOC688105 hypothetical protein LOC688105; LOC360590
45 chr16 6562495 6562603 1.71E-07 2931 NT5DC2 5’-nucleotidase domain containing 2
46 chr16 22377983 22378135 1.74E-07 21756 SLC18A1 solute carrier family 18 (vesicular
monoamine), member 1
47 chr6 75731811 75731965 1.97E-07 587 NFKBIA nuclear factor of kappa light polypeptide
gene enhancer in B-cells inhibitor, alpha
48 chr8 68790635 68790830 2.10E-07 −84 Rab11a RAB11a, member RAS oncogene family
49 chr8 44864109 44864180 3.27E-07 188782 SORL1 sortilin-related receptor, LDLR class A
repeats-containing
50 chr8 124992930 124993041 4.02E-07 237699 Cx3cr1 chemokine (C-X3-C motif) receptor 1
The 50 most significant GR-binding sites (GBS) as determined by CLCbio workbench software. Per GBS, the p-value is indicated as well as the nearest gene and
the distance relative to the Transcription Start Site (TSS) of this gene. Negative numbers indicate a location upstream of the TSS, positve numbers downsteam of
the TSS. GBS that are located intragenically are indicated in bold print.
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dated in neuronal PC12 cells were associated with genes
that have a known neuronal function, such as dopamine
decarboxylase (Ddc) and tyrosine hydroxylase (TH), both
important enzymes in the biosynthesis of catecholamines.
Other examples are voltage-gated potassium channel sub-
unit beta-1 (Kcnab1), NMDA receptor-regulated gene 2
(Narg2), Period circadian protein homolog 1 (Per1) and
neurofascin (Nfasc).
GR-binding sites and regulation of nearby genes
RNA was isolated from neuronal PC12-cells to estab-
lish whether GR activation by DEX-treatment induced
expression of the genes closest to the validated GBS.
Six out of 14 genes (Per1, Ddc, Kcnab1, Pik3r5,
Il20ra, Th) showed a significant upregulation upon
GR activation and another 2 genes (Frmd8 and Tle3)
a clear trend towards significance with p-values of
0.055 and 0.051 respectively (Figure 3C). One gene,
Ddit4, was downregulated by GR activation rather
than upregulated. Five out of the 14 genes tested did
not show a change in expression at the time point
measured, i.e. 3 hours after GR activation. Eight out of
14 tested genes contained a GRE, including the GBS near
Ddit4.
Overlap with GR-binding sites in other tissues is limited
We next compared the GR binding regions in rat neur-
onal PC12 cells to two previously published GR ChIP-Seqstudies performed in human lung carcinoma (A549) [26]
and mouse adipocytes (3T3-L1) [27]. This resulted in a
list of GBS unique to neuronal PC12 cells and lists of
GBS shared with either or both of the other cell types.
The majority of GBS identified in PC12, 1,031 in total,
appeared unique to neuronal PC12 cells. Only 79 (7%) of
the GBS identified in PC12 cells were shared with A549
cells and 127 (11%) with 3T3-L1 cells (Figure 4). A similar
degree of overlap was observed comparing GBS of A549
and 3T3-L1 cells, that shared a total of 510 GBS being
12% and 6% respectively. Only 54 GBS (4%) of all PC12
GBS were common to all 3 cell types.PC12-specific GBS are located nearby genes with a
neuronal function
To analyse which biological processes are likely to be
affected by GR-binding in neuronal PC12 cells, the genes
nearest to the GBS were analysed for overrepresentation
of specific gene ontology classes using DAVID [38,39].
Genes closest to 1,031 sites uniquely identified in PC12
cells were used as input in the analysis. The genes near
PC12-unique GBS had a high representation of GO-
terms linked to neuronal function and clustering of all
identified GO-terms revealed that the most enriched
cluster in this group was “neuron development”, with
other neuron-related clusters being “neuron projection”,
“synapse” and “biogenic amine biosynthetic process”
(Table 2).
Neuronal PC12 
(rat) - + + + + + + + + + + + + + + + + +
3T3-L1 (mouse) - - - - - - - - - - + - - + + + - +




Figure 3 Validation of GR binding sites and effects on mRNA expression. A ChIP-PCR validation of identified GBS, previously shown to be
GR-targets in literature (grey bars) or representing newly identified GBS (black bars). The genes that are associated with the GBS are listed on the
x-axis. The y-axis represents the % of input DNA that was bound by the GR after subtracting the aspecific IgG-bound fraction and the amount of
GR bound after vehicle (VEH) treatment. The error bars represent the standard error of the mean (SEM) when comparing the DEX-induced GBS
versus the VEH-induced GBS. An unpaired two-tailed T-test was used for statistics. B Diagram indicating whether the known GR-binding regions
were previously detected in other published GR-ChIPseq studies based on BlastZ-based interspecies conservation (http://main.g2.bx.psu.edu/) [37].
The genomic locations corresponding to the GBS are listed in Additional file 3: Table S3 as region numbers 1 (Ddc), 7 (FRMD8), 8 (Per1), 11 (Snx7),
14 (Il20ra), 17 (Th), 75 (TLE3), 94 (Ddit4), 345 (Olr1735), 352 (Fndc7), 366 (Pik3r5), 526 (Cry2), 704 (Nfasc), 842 (Narg2), 976 (Kcnab1), 1020 (Ctsd). C
mRNA expression of the genes associated with the validated GBS after DEX-treatment relative to VEH-treatment (100%). Expression was
normalized against tubulin 2a mRNA expression. The non-parametric Wilcoxon Signed Ranks Test was used for statistics.
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majority of GR binding is to genomic regions that are
nearby or within genes with a known neuronal function.
The full list of GO terms of the genes associated with
the PC12-unique GBS are available in the additional ma-
terial (Additional file 2: Table S2).GR binding sites represent both transactivation and
transrepression modes of action
Screening the significant GBS with MEME and TOM-
TOM for presence of known DNA-motifs revealed that
683 (58%) regions contained a Glucocorticoid Response
Element (GRE). The identified GRE-motif was similar to
Neuronal PC12 cells 







Figure 4 Venn diagram representing overlap between GR-targets in different ChIP-Seq studies. The overlap of GBS identified in PC12 cells
is compared to those genomic regions bound by GR in two other ChIP-Seq studies in human lung carcinoma cells (A549) [26] and mouse
adipocytes (3T3-L1) [27].
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prevalence [25,26]. This indicates that more than half of
the GBS are most likely involved in transactivational
effects of GR on gene transcription. We subsequently
subdivided the list of GBS into a group of GBS with
GREs, in which GR presumably exerts its actions via
transactivation and the remainder without GREs, in
which GR in all probability operates via transrepression
of other transcription factors. Strikingly, the most sig-
nificant GBS were enriched for GREs, while non-GRE
containing GBS tended to have a lower p-value in the
ChIP-Seq data (Figure 5). More than 80% of the top 100
most significant GBS contained a GRE, dropping to ap-
proximately 50% for GBS ranking lower in the list from
position 400 downwards.Table 2 Top 10 enriched functional GO clusters in neuronal P





4 metal ion binding
5 blood vessel development
6 cell motion
7 identical protein binding
8 biogenic amine biosynthetic process
9 synapse
10 protein tyrosine kinase activity
Gene ontology analysis of genes associated with GBS identified in neuronal PC12 c
found in neuronal PC12 cells. Analysis was performed with the Database for Ann
GO-term is shown. In addition, the category to which the GO term belongs to is
Compartment (CC). The enrichment score indicates the geometric mean (in -logNot only the significance of the GBS differed between
GRE and non-GRE containing binding sites, but also
their composition in terms of motifs for transcription
factor binding differed considerably. Both groups were
subjected to de novo motif discovery to investigate the
prevalence and identity of other motifs representing
transcription factor binding sites within the binding
regions. A total of 225 (33%) of the 683 GRE-containing
GBS represented simple GREs, only harbouring a GRE-
like sequence but no other motifs (Figure 6). However,
the majority of the GRE-containing GBS represented so
called composite sites and also contained one or more
other motifs besides the GRE. In the group of GRE-
containing genomic regions a motif for binding of Acti-












ells. The 10 most enriched functional GO clusters in GBS that are uniquely
otation, Visualization and Integrated Discovery (DAVID). Per cluster, the first
indicated, i.e. Biological Processes (BP), Molecular Function (MF) or Cellular
scale) of p-value of the GO cluster.
683 GRE-containing GBS (58%) 500 NON GRE-containing GBS (42%)























Figure 6 MEME de novo motif discovery within GBS. A. Motifs for transcription factor binding in the 683 GBS that contain a GRE-like
sequence. B. Motifs for transcription factor binding in the 500 GBS without a GRE. Analysis was performed within a 200 bp-frame containing the
GBS-centre in the middle. The frequency of identified motifs in the PC12-dataset is indicated as well as transcription factors of which the known
binding motif most significantly matches the identified motif. Only motifs with an E-value < 1E-5 are depicted.
Figure 5 Significance of GR-binding sites with and without a GRE. GR binding sites containing a GRE-like sequence have smaller p-values in
the ChIP-Seq data compared to those regions without a GRE. On the x-axis the 1183 GBS are ranked into BINs consisting of 100 binding regions
ranked according to significance. For example, the 100 most significant GBS are represented in BIN 1 (1–100), while the 83 least significant GBS
are represented in the last BIN (1101–1183). On the y-axis the percentage of GRE and non-GRE containing GBS per BIN is indicated.
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Figure 7 The most frequent motif-combinations within the GBS. Specific combinations of motifs for transcription factor binding were
observed, with differences in occurrence and frequency between the GBS with and without a GRE. TF: transcription factor.
Polman et al. BMC Neuroscience 2012, 13:118 Page 9 of 17
http://www.biomedcentral.com/1471-2202/13/118followed by motifs for binding of GA binding protein
transcription factor, alpha subunit (Gabpa), Zinc Finger
Protein 281 (Zfp281) and paired related homeobox 2
(Prrx2) (Figure 6). An entirely different distribution of
motifs was observed in the genomic regions that did not
contain a GRE. Interestingly, two motifs were identified
that were unique for the regions without a GRE: a motif
for binding of zinc finger and BTB (bric-a-bric, tram-
track, broad complex)-domain- containing 3 (ZBTB3)
gene, present in over 80% of the regions, and a motif for
binding of GATA binding protein 1 (GATA1), present in
15% of the genomic regions (Figure 6). Besides differ-
ences there were also some motifs found in both groups,
regardless of whether the regions contained a GRE or
not. For example, in both groups motifs corresponding
to AP-1, Prrx2 and Zfp281 were identified, albeit at
different frequencies.Table 3 Top 10 enriched functional GO clusters in GR binding
GBS with GRE
GO Term Category Enrichment score
1 cell motion BP 4.2
2 protein kinase binding MF 3.5
3 vasculature development BP 3.3
4 protein dimerization activity MF 2.9
5 metal ion binding MF 2.8
6 regulation of apoptosis BP 2.3
7 apoptosis BP 2.2
8 regulation of myeloid cell
differentiation
BP 2.1
9 cell adhesion BP 1.9
10 cytoplasmic vesicle CC 1.8
The 10 most enriched functional GO clusters in GBS that do or do not contain a GR
Discovery (DAVID). In both cases the GO-term that best represents the annotation c
indicated, i.e. Biological Processes (BP), Molecular Function (MF) or Cellular Compart
of p-value of the GO cluster.Next, the co-occurrence of the various motifs was
investigated. In the GRE-containing group, 26% of the
GBS contained an AP-1 site besides a GRE, making it
the most prevalent combination of transcription factor
binding sites. Other frequently observed combinations of
motifs were a GRE in conjunction with motifs for bind-
ing of Gabpa, Zfp281 and Prrx2 (Figure 7). In the group
without a GRE, all frequently observed combinations of
motifs included Zbtb3. The most frequently observed
combination was Zbtb3 in conjunction with Prrx2 (in
30% of the regions), followed by combinations of Zbtb3
with AP-1, GATA1 and Zfp281.
Different biological processes are regulated via
transactivtion and transrepressive modes of action
We subsequently investigated whether GBS that contain
a GRE regulated different biological processes than thoseregions(GBS) with and without a GRE
GBS without GRE
GO Term Category Enrichment score
neuron projection morphogenesis. BP 3.8
cytoplasmic vesicle CC 2.5
metal ion binding MF 2.4
phospholipid binding MF 2.3
catecholamine biosynthetic process BP 2.2
protein complex assembly BP 2.0
muscle cell development BP 1.9
neuron projection regeneration BP 1.6
actin filament binding MF 1.6
synaptic transmission BP 1.6
E according to the Database for Annotation, Visualization and Integrated
luster is shown. In addition, the category to which the GO term belongs to is
ment (CC). The enrichment score indicates the geometric mean (in -log scale)
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pression modes of action respectively. Genes near GRE-
containing GBS showed an involvement in general cell
functions and processes such as apoptosis, cell motion,
protein dimerization activity and vasculature develop-
ment (Table 3). In contrast, genes near regions without a
GRE had a clear role in neuronal processes such as
neuron projection morphogenesis, neuron projection re-
generation, synaptic transmission and catecholamine
biosynthetic process. The full list of GO terms of the
genes associated with GBS with and without GREs are
available in the additional material (Additional file 3:
Table S3).
Discussion
GR is widely expressed throughout body and brain and
is an important transcriptional regulator of a diversity of
biological processes, ranging from glucose and lipid
homeostasis to immune suppression and cell prolifera-
tion and differentiation. Today several ChIP-Seq studies
have been published focusing on genome-wide discovery
of GR binding in different cell types [24-27], and these
studies have contributed immensely to our understand-
ing of GR-signalling. What has become apparent, is that
GR-binding is highly cell type-specific with minimal
overlap in GBS between different cell types. Therefore,
in order to gain insight into cell type-specific GR targets
or mechanisms it is essential to investigate GR-signalling
in a specific cell system or tissue of interest.
Here we present the first genome-wide discovery of
GR-binding sites in a neuronal context. GR is an import-
ant transcription factor in neurons and is known to exert
effects on neuronal structure and plasticity. So far the
focus on GR-mediated action of glucocorticoids in a
neuronal context has remained largely in the dark and
most of the knowledge on GR modes of action, GR
responsive genes and pathways and crosstalk partners of
GR has come from studies on peripheral tissues includ-
ing the immune system, the respiratory tract, skeletal
muscle and adipose tissue as well as various types of can-
cer cells [40-42]. Approximately 1,100 genomic binding
sites of GR were identified in neuronal PC12 cells, the
majority of which are novel and display only very limited
overlap with GR binding sites in other non-neuronal cell
types. Moreover, most of the identified GR-binding sites
were located in the vicinity of genes with a neuronal
function. Finally, we identified several motifs for tran-
scription factor binding that may represent novel cross-
talk partners of GR in neurons.
Reliability of ChIP-Seq data
We assessed whether our ChIP-Seq data met different
reliability criteria. First, a very high proportion (16 out
of 17 = 94%) of ChIP-Seq peaks covering a wide range ofp-values could be validated using ChIP RT-qPCR in
chromatin derived from an independent experiment.
Second, several GBS were located in the vicinity of
known GR-target genes. Third, 13% of the identified
GBS overlapped with previously identified GBS in other
tissues (mouse adipocytes and human lung carcinoma
cells). Finally, highly significant motifs resembling GREs
were detected in almost 60% of the peaks. Together
these criteria underscore the high quality of our
ChIP-Seq dataset of 1183 GBS.
Genomic binding sites of GR by far exceed GR-responsive
genes
The number of GBS identified in PC12 cells (1,183) was
relatively low compared to other studies, i.e. 4,392 GBS
in human lung carcinoma (A549) and 8,848 GBS in
mouse adipocytes (3T3-L1) [25-27]. However, this could
be the consequence of the high stringency we applied,
supported by the high validation rate of GR-binding to
16 out of 17 selected GBS. We cannot exclude that the
actual number of genomic regions exhibiting GR-
binding in PC12 cells may be considerably higher. Com-
parison of GBS between different tissues is hampered by
the different thresholds used in different studies without
a standard accepted cut-off for reliability of ChIP-Seq
data. Nonetheless, the identified GBS still considerably
outnumbered by more than 10-fold the differentially
expressed genes observed after a single 100 nM cortico-
sterone pulse in neuronally differentiated PC12 cells
[31]. In fact, this is a more general observation that
applies to several of the ChIP-Seq studies on GR so far
[25-27]. In A549 cells, for example, 1 hour of DEX-
stimulation resulted in the identification of 4,392 GBS,
whereas only 234 genes were differentially expressed at
this time-point. Similarly in 3T3-L1 cells, 8,848 GBS
were identified and 620 genes were found to be DEX-
responsive after 6 hours. It therefore seems likely that
GR-binding to genomic sites is a measure of the potential
of GR to mediate effects on gene expression of nearby
genes rather than a direct predictor of whether a gene is
differentially expressed. Whether this potential is con-
verted to an actual effect on transcription most likely
depends to a large extent on the availability and binding
of other TFs.
To further examine the relationship between GR-
binding and regulation of gene expression of nearby
genes, we tested whether GR activation by DEX regu-
lated expression levels of the genes closest to the vali-
dated GBS. In approximately half of the cases we could
validate differential mRNA expression of the associated
genes, illustrating the functionality of GR-binding. This
percentage is quite high, considering that for the tested
genes the GBS were often located at large distances from
the genes we tested and not necessarily in classical
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binding sites the overlap with responsive genes as identi-
fied by DNA microarray was only 6.5%, despite the fact
that only binding sites for PAX8 located within 1 kb of a
TSS were taken into account [43].
However, this also means that in the other half of the
cases we were not able to confirm an effect of GR-
binding on expression of the closest gene. There are sev-
eral possible explanations for this. First, maybe the near-
est gene is not necessarily the most relevant gene for
studying functional effects of GR-binding. Another ex-
planation is that we measured gene expression at the
wrong moment. Since GR binding precedes effects on
gene expression, we chose to measure mRNA expression
after 3 hours of DEX-exposure. We therefore cannot ex-
clude that the genes that were not GC-responsive at this
moment might still be regulated by GR, albeit at differ-
ent time-points or under different conditions. Temporal
dynamics of individual genes are known to differ
[31,44,45], which may explain why not all genes with a
nearby GBS are responsive to DEX at one given time-
point. Investigating gene expression at other time-points
would be necessary to determine this. In addition, meas-
uring mRNA may not be sensitive enough to pick up the
effects of GR-binding on gene expression in all cases.
Conway-Campbell et al. showed that administration of
pulses of corticosterone to adrenalectomised rats
resulted in pulsatile GR-binding to the Per1 promoter
region followed by a burst of transcription, which was
measurable by qPCR of nascent heterogeneous nuclear
RNA but was not obvious from measuring mRNA levels
[45], despite the fact the Per1 is a well-established GR
target gene. This may therefore also be the case for the
genes in this study that showed no or a small change in
expression 3 hrs after DEX administration. Finally, we
can not exclude that some of the GBS are derived from
unspecific binding at spurious genomic locations, due to
the applied continuous dosing regime with the synthetic
GC DEX, rather than pulsatile exposure to the endogen-
ous ligand, explaining why differential expression of the
nearest gene was not observed.Genomic location of GBS
What is becoming increasingly clear is that the majority
of GBS are not located in promoter regions upstream of
the transcription start site of genes or in the 5’UTR. In
fact, only 9% of the significant GBS identified in the
current study were located within 10kb upstream of the
TSS and an additional 5% were located within the 5’UTR.
In contrast, a higher number of GBS (11%) were located
at a distance >100kb upstream the TSS. These distant
regions might be functional, since it is known that tran-
scription factor binding sites are able to exert effects ongene expression through chromosome folding and there-
fore can be effective at large genomic distances [46].
A much higher percentage of GBS occurred in intra-
genic regions, almost exclusively in introns, representing
31% of the total list of significant GBS. A similar
phenomenon was observed in 3T3-L1 adipocytes, where
48% of the GBS were found in intragenic regions, either
in exons or introns [27]. Why intragenic regions show
so much GR binding is at the least intriguing. Studies
using artificial constructs in luciferase reporter assays
have suggested that intronic GBS contain GREs with
functional properties [27].
The 1,183 GBS identified in this study were associated
with considerably fewer than 1,183 different genes, given
that there were many examples of multiple GBS being
located in each others vicinity nearby the same gene. An
example is Disks large homolog 2 (Dlg2), that had 7 dif-
ferent GBS located nearby or Tolloid-like protein 1
(TLL1) with 5 GBS nearby. A question that still needs
answering is whether the most nearby gene to a GBS is
in fact the most likely candidate to be transcriptionally
regulated by GR binding, or whether multiple genes
could be affected. Several GBS had multiple genes in
their vicinity. To solve this point linking ChIP-Seq studies
on TF-binding with expression studies remains import-
ant, as well as performing studies in which GBS are
mutated in their natural chromatin environment to inves-
tigate the effect on transcription of nearby genes.
Tissue-specificity of GR-binding reveals a neural signature
The majority of the GBS identified in this study were
novel and unique to neuronal PC12 cells and were located
nearby genes with a high representation of GO-terms
linked to neuronal function. For example, one of the
enriched GO clusters among the genes near PC12-unique
GBS was “biogenic amine biosynthetic process”, which
refers to the biosynthesis of biologically active amines,
such as norepinephrine, histamine, and serotonin, many
of which act as neurotransmitters. Indeed, we identified
GBS in the vicinity of a number of genes involved in the
synthesis of catecholamines, such as dopamine decarb-
oxylase (Ddc) (Additional file 1: Table S1: regions nr. 17
and 34) and tyrosine hydroxylase (TH) (Additional file 1:
Table S1: region 1). “Neuron projection” was another of
the enriched GO clusters and accordingly several GBS
were located in the vicinity of genes that play a role in
outgrowth of axons, such as the semaphorins SEMA3E
and SEMA5A (Additional file 1: Table S1: regions 529,
663, 774 and 891 respectively), proteins that act as axonal
growth cone guidance molecules [47]. Four other GBS
were located nearby SLIT2 (Additional file 1: Table S1: re-
gion 455) and SLIT3 (Additional file 1: Table S1: regions
53, 750 and 1134), molecules that act as guidance cues in
cellular migration [48]. In addition, several GBS near
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as the serotonin receptors HTR1A, HTR1D, HTR1F and
HTR2A (Additional file 1: Table S1: regions nr. 660, 284,
1070 and 807 respectively) and 18 GBS located near a
wide variety of voltage-gated potassium channel subunits,
including KCNA3, KCNA4, KCNAB1, KCNC1, KCNH1,
KCNH2, KCNH6, KCNK9 and KCNMA1, which play a
role in neuronal excitability and neurotransmitter release
[49]. Finally, several GBS were located nearby the synap-
totagmins SYT1 (Additional file 1: Table S1: region 752,
1011, 1159), SYT13 (Additional file 1: Table S1: region
1032) and SYT17 (Additional file 1: Table S1: region 280,
879, 1019) which are integral membrane proteins of syn-
aptic vesicles thought to participates in triggering neuro-
transmitter release at the synapse [50]. These are just a
few of the many examples of GBS located in the vicinity
of genes with neuronal function. Tissue-specific co-fac-
tors or transcription factors likely mediate binding of GR
to the DNA or alter chromatin accessibility, resulting
in these distinct tissue-specific patterns of GR-binding.
The overlap in GBS with other tissues was low, with
only 7% and 11% of the GBS overlapping with A549 cells
3T3-L1 cells respectively and is very much in line with
what has been observed in expression studies and other
GR ChIP-Seq studies. For example, comparison of mouse
mammary and mouse pituitary cells revealed an overlap
of 4.5% and 11.4% respectively of the total number of
GBS identified in either of the cell types [25]. A similar
high degree of tissue-specificity has also been observed
for other TFs, such as STAT3, where an overlap of only
34 of 1352 (2.5%) identified STAT3 binding sites was
observed when comparing ChIP-Seq data derived from 3
different tissues (mouse peritoneal macrophages. mouse
embryonic stem cells and CD4+ T cells [51].
Potential crosstalk partners of GR of relevance for
neuronal function
GR operates in conjunction with an extensive network
of other TFs. Previous studies in a non-neuronal setting,
e.g. involving the immune system, muscle and adipose
tissue, have generated extensive knowledge on GR-
binding to the genome, the motifs that are recognized by
GR and the transrepression partners that it can inhibit
by protein-protein interaction [19,40-42]. However, con-
firmation of this knowledge in a neuronal context is
lacking.
The importance of other TFs for GR-function is evi-
dent from the high percentage of GBS consisting of
composite GREs or binding sites for multiple TFs we
observed in this study. Only twenty percent of the iden-
tified GBS consisted of simple GREs, harbouring a GRE-
like sequence but no other motifs. The vast majority of
the GBS were composite sites containing binding motifs
for multiple TFs. This included composite GREs thatcontained a GRE in addition to one or more other
motifs, as well as tethering GBS that did not contain a
direct binding site for GR but most often a combination
of motifs for TF-binding. Motifs for binding of AP-1,
were frequently observed in the GBS in PC12 cells, both
in combination with a GRE as well as in tethering sites.
AP-1 is a well-known crosstalk partner of GR [52] and
AP-1 binding sites overlap extensively with GR binding
sites [53]. Interestingly, however, we also observed a
number of motifs for TFs within the GBS that may rep-
resent novel crosstalk partners of GR that are relevant in
a neuronal context.
In composite GREs, besides AP-1, three different
motifs were abundantly observed, corresponding to
binding sites for Gapba, Zfp281 and Prrx2. In tethering
sites, the most frequently observed motif was a binding
motif for Zbtb3, occurring in more than 80% of the GBS
and by far outnumbering AP-1 motifs which had a fre-
quency of only 18%. Other abundant motifs represented
binding sites for GATA1, Zfp281 and Prrx2. For many of
these TFs information in literature is sparse. Moreover, a
link to neuronal function and/or GR has not been
reported.
Zfp281 is a GC-box binding transcription factor and is
involved in the regulation of genes implicated in pluripo-
tency of murine embryonic stem cells [54,55]. Recently,
we identified GC-box associated motifs in flanking
regions surrounding GREs of hippocampal CORT-
responsive genes. The presence of a GC-box motif in
close proximity to the GRE correlated with GR-binding
in the hippocampus, but not in other non-neuronal cell
types [56]. We hypothesized that GC-boxes may play a
role in determining tissue specificity of GR binding to a
defined group of GREs. The GC-box motif we identified
in hippocampus resembled the binding motif of the
MAZ TF which is in fact very similar to the Zfp281 motif
identified in neuronal PC12 cells (Figure 6). According to
Allen Brain Atlas [57], both MAZ and Zfp281 are very
highly expressed in the mouse brain, especially in the
hippocampus. Either one might be a novel crosstalk part-
ner of GR in a neuronal context.
Gabpa, also known as nuclear respiratory factor 2 alpha
(NRF2a), is a DNA-binding unit of the GA binding pro-
tein transcription factor which is involved in the nuclear
control of mitochondrial function in neurons [58,59].
Gabpa responds to an altered energy demand within pri-
mary neurons by altering the expression of mitochondrial
genes [60] and has been implicated in neuronal viability
after brain injury [61]. Prrx2 is a member of the paired
family of homeobox proteins, and is mainly known for its
essential role in orofacial development [62]. It was re-
cently discovered to be a novel pituitary transcription
factor [63]. Otherwise very little is known on this TF and
it has not been linked to GR-signalling before.
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essential role in hematopoiesis [64]. GR was reported to
interfere with GATA-1 function and inhibits the expres-
sion of erythroid structural genes [65]. Zbtb3 was
observed in over 80% of the GBS that did not contain a
GRE and was encountered in all frequently observed
combinations of TFs binding sites in tethering GBS.
Zbtb3 belongs to a family of transcription factors, many
of which are important for B and T cell differentiation.
A recent modeling study indicated that Zbtb3 may be a
remote homologue of the Drosophila GAGA factor
which is involved in both gene activation and gene re-
pression and plays a role in the modulation of chromatin
structure [66]. Zbtb3 contains a BTB domain, which
plays a role in protein dimerization and transcriptional
repression and interacts with histone deacetylase core-
pressor complexes such as NCoR (nuclear receptor core-
pressor) and SMRT (silencing mediator of retinoic acid
and thyroid hormone receptor) [67-69]. Relevance for
the brain has not been indicated yet.
It must be noted that linking the de novo motifs to
binding sites of known proteins is difficult and since in
many cases more proteins can bind to a given motif,
additional ChIP-experiments would need to be per-
formed to address experimentally whether the TFs
described above and predicted by TOMTOM actually
bind to the DNA at the identified genomic regions.Non-GRE containing tethering GBS are associated with
genes involved in aspects of neuronal function
More than half of the GBS (58%) contained a GRE.
Interestingly, the GRE-containing GBS were located near
other types of genes than those without a GRE, as
revealed by GO-analysis of the most nearby genes. While
the GRE-containing GBS associated with more general
cell functions such as apoptosis, cell motion, protein
dimerization activity and vasculature development, the
GBS without a GRE were more often located near genes
involved in neuronal function. Motif analysis of the 54
sites in common between PC12, A549 and 3T3-L1 cells
revealed that 91% contained a GRE (data not shown).
This suggests that there is a core set of ubiquitous GBS
that regulate key cellular processes in multiple tissues by
the transactivation mode of action. On the other hand,
tissue-specific TFs appear to play a role in tethering GR
to genomic regions in a cell type-specific manner, regu-
lating particular biological processes relevant for the tis-
sue of interest. Of course many of the GRE-containing
GBS were also unique to neuronal PC12 cells. In these
cases it seems likely that tissue-specific TFs facilitate
binding of GR to the chromatin, guiding it to GREs that
are relevant for that particular tissue. It has been shown
by John et al. that this cell type-specificity ispredetermined by differences in chromatin landscapes
which affect the accessibility of GR to bind to its targets
[25].
Conclusions
In this study we identified over 1,100 GBS in neuronal
PC12 cells, the majority of which were unique and
exhibited very little overlap with GBS in other cell types.
The PC12 unique GBS were located in the vicinity of
genes involved in neuronal functions such as axonogen-
esis, neuron differentiation and neuron development.
Moreover, we confirmed that in more than half of tested
GBS the most closely located gene was indeed GC-re-
sponsive, suggesting that these GBS play a role in GC-
dependent transcriptional control. Intriguingly, we found
striking differences in the identity of genes near GBS
with or without a GRE. GBS containing a GRE were
more often located nearby genes involved in general cel-
lular functions such as regulation of cell proliferation
and intracellular signaling, while tethering GBS, in which
GR is indirectly bound to the DNA via another TF, were
more often located near genes involved in neuronal
function. Finally, we characterized the motif content of
the GBS and identified a number of binding sites for
TFs that may represent novel crosstalk partners of GR in
neurons, and would vastly expand the repertoire of TFs
in the GR interactome. Future studies should focus on
confirming the binding of these predicted TFs within the
identified GBS and on establishing their role as neuronal
crosstalk partners of GR and their relevance in other
neuronal cell types.
We conclude that the current ChIP-Seq study in neur-
onal PC12 cells has provided insight into some exciting
new aspects of GR-mediated action of glucocorticoids in
a neuronal context, an area which has so far remained in
the dark. Understanding GR-signalling in a neuronal
context is important given the profound effects of gluco-
corticoids on neuronal plasticity and consequently on
brain function.
Methods
Cell culture and harvest
Rat pheochromocytoma PC12 cells were cultured and
differentiated for ten days with NGF as described be-
fore in collagen-coated culture flasks (75 cm2 and 175
cm2 for mRNA-analysis and chromatin immunopreci-
pitation (ChIP) respectively; Becton Dickinson) [31].
On the last day of differentiation, the cells were stimu-
lated continuously for 90 minutes or 180 minutes with
either 100 nM Dexamethasone (DEX) or ethanol
(0.1%) in corticosteroid-depleted medium for ChIP or
mRNA analysis respectively. For ChIP, after 90 minutes
incubation the protein-DNA interactions were fixed by
crosslinking for 10 minutes with 1% formaldehyde
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were incubated for 10 minutes with 0.125 M glycine.
After discarding the medium, the cells were washed
twice with phosphate buffered saline (PBS) containing
Phenylmethanesulfonyl fluoride solution (PMSF; Fluka,
Steinheim, Switserland). Finally, the cells were collected
in PBS containing Protease Inhibitors (PI, Roche,
Mannheim Germany). The centrifuged cell pellet
was stored at −80°C until sonication. For sonication,
the defrosted cell pellets were dissolved in 0.6 ml
PI-containing RIPA (0.1% SDS, 1% NaDOC, 150mM
NaCL, 10mM Tris pH 8.0, 2mM EDTA, 1mM NaVO3,
1%NP-40, β-glycerolphophate and Na-butyrate) and
incubated on ice for 30 minutes. Subsequently, the chro-
matin was sheared (Bioruptor, Diagenode; 25 pulses of 30
sec., 200 W), resulting in chromatin fragments of 100–
500 bp. The sheared chromatin-containing supernatants
were stored at −80°C until use in the ChIP-procedure.
For the mRNA-analysis (n=6), the cells were harvested
after 180 minutes incubation with 100 nM DEX and total
RNA was isolated using Trizol reagent (Invitrogen Life
Technologies, Carlsbad, USA) according to manufac-
turer’s protocol.ChIP-Seq
For ChIP Sepharose A beads (GE Health care, Uppsala
Sweden) were blocked with 1 mg/ml BSA (Biolabs, Ips-
wich, UK) and 0.2 mg/ml fish sperm (Roche) for 1 hr at
4°C. Three independent ChIPs each were performed on
chromatin (60–120 μg per treatment) of the same batch
of differentiated cells. Per ChIP the chromatin was pre-
cleared by incubation with blocked beads for 1 hr. After
preclearing, an input sample was taken to control for
the amount of DNA that was used as input for the ChIP
procedure. The remaining sample was divided into two
samples, each incubated O/N at 4°C under continuous
rotation with either 6 μg of ChIP-grade GR-specific
H300 or normal rabbit IgG antibody (Santa Cruz
Biotechnology, California, USA). Subsequently, the
antibody-bound DNA-fragments were isolated by incu-
bating the samples with blocked protein A beads for 1 hr
at 4°C. The beads were washed 5 times in 1 ml washing
buffer (1x low salt; 1x high salt; 1x LiCl; 2x TE according
to Nelson et al. [70]) after which they were incubated
with 0.25 ml elution buffer (0.1M NaHCO3; 1% SDS)
for 15 min (RT, continuous rotation) to isolate the
DNA-protein complexes. To reverse crosslink the
DNA-protein interactions, the samples were incubated
O/N at 65°C with 0.37M NaCl. RNAse treatment (0.5 μg/
250 μl; Roche, Mannheim, Germany was performed for
1 hr at 37°C followed by purification of DNA fragments on
Nucleospin columns (Macherey-Nagel, Düren Germany).
The immunoprecipitated samples were eluted in 50 μlelution buffer [70]. Half of one ChIP-sample was used
for sequencing.
For sequencing, DNA was prepared according to the
protocol supplied with the Illumina Genome Analyser
GA1. In brief, the DNA fragments were blunted and
ligated to sequencing adapters after which the DNA was
amplified for 18 rounds of PCR. The DNA was electro-
phoresed on a 2% Agarose gel, of which a region con-
taining DNA fragments 100–500 bp in length was
excised. Subsequently, DNA was isolated from this gel-
slice with the Qiagen Gel Extraction Kit. DNA quality
was checked on the Agilent Bioanalyser (Waldbronn,
Germany). Single end sequencing of the first 36 bp of
the resulting DNA library was performed on the Illu-
mina Genome Analyser (Leiden Genome Technology
Center, Leiden University Medical Center).
Peak calling and mapping
The single-end read sequences were aligned to the refer-
ence rat genome (RGSC v3.4) using the CLC genomics
workbench 3.6.5 (Aarhus, Denmark), according to the
default settings which allowed up to 1 mismatch per
read or 2 unaligned nucleotides at the ends. Subse-
quently, DEX-induced peaks were detected using the
CLC workbench peak finding algorithm in which the
null distribution of background sequencing signal was
set for both treatments at 1200 bp and the maximum
false discovery rate at 5%. Further settings were left
at default. Using Galaxy (http://main.g2.bx.psu.edu/)
[37,70,71], Refseq genes in the vicinity of the GBS were
determined. As a reference genome Rattus Norvegicus 4
(rn4) was used. Data was visualized by uploading wiggle-
files containing the raw ChIP-Seq data on the UCSC
genome browser (http://genome.ucsc.edu).
Motif search
The regions containing the GBS were trimmed to
200bp-width sequences and screened for de novo motifs
using MEME [70,72]. The 500 most significant GBS
were screened for motifs consisting of 8 to 40 nucleo-
tides. The 15 most significant motifs were given as out-
put. Using TOMTOM [73], the identified motifs were
compared against databases of known motifs.
Comparison of PC12 GBS with other datasets
The genomic regions identified in the PC12 cells were
compared to two published datasets consisting of GR-
bound genomic regions in human A549 cells [26] and in
mouse adipocytes [27]. For this purpose, the significant
regions of the published datasets were converted to rat
equivalents using the Galaxy website (http://main.g2.bx.
psu.edu/) under default conditions. Subsequently, these
rat regions were compared to the PC12 GR-bound
regions and overlap was calculated using Galaxy [37,71].
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The nearest genes surrounding the significant GBS were
analysed with The Database for Annotation, Visuali-
zation and Integrated Discovery (DAVID) v6.7 (http://
david.abcc.ncifcrf.gov/home.jsp). As a cutoff, the bio-
logical processes (BP) that had a Benjamini-Hochberg
p-value <0.05 were considered to be significant. Clus-
tering all the identified GO-terms according to their
functional annotation was performed under medium
classification stringency (standard setting at DAVID).RT-qPCR
RT-qPCR was performed to validate GR-binding to iden-
tified GBS using the immunoprecipitated chromatin as
input. PCR was conducted using the capillary-based
LightCyclerW thermocycler and LightCycler WFastStart
DNA MasterPLUS SYBR Green I kit (Roche, Mannheim,
Germany) according to manufacturer’s instructions. The
primers were designed in NCBI/Primerblast according
to the following criteria: (a) PCR product size between
80 and 150 bp; (b) an optimal primer size of 20 bp; (c)
an optimal Tm of 60°C; (d) amplicon aimed at the centre
of the GBS.
The ChIP PCR signal was normalized by subtracting the
amount of nonspecific binding of the IgG antibody in the
same sample. This was then calculated as a percentage of
the amount of input DNA which was originally included
into the ChIP procedure. Known GBS upstream of DNA
damaged induced transcript 4 (Ddit4) [56] and Metal-
lothionein 2A (MT2a), served as positive controls for the
ChIP. As a negative control, exon 2 of Myoglobin 2 (MB)
was amplified. MB is involved in oxygen storage in muscle
cells and does not contain a GRE to our knowledge. All
selected GBS were measured in three independently per-
formed ChIPs, resulting in 3 measurements per validated
genomic location. Normalized data were analysed with
GraphPad Prism 5 (trial version 5.00; GraphPad Software,
Inc.). An unpaired two-tailed T-test was used to assess sig-
nificant GR-binding. All primer sequences for mRNA and
ChIP validation are listed in Additional file 4: Table S4
and Additional file 5: Table S5 respectively.
For mRNA analysis, cDNA was synthesized using the
iScript cDNA synthesis kit (Bio-Rad, California, USA),
according to manufacturer’s instructions. PCR was con-
ducted as described above. All PCR reactions on cDNA
were performed in duplo. The standard curve method
was used to quantify the expression differences [74].
cDNA values were normalized against Tubb2a expres-
sion levels. Normalized data was analysed with Graph-
Pad Prism 5. The non-parametric Wilcoxon Signed
Ranks Test was used to assess significant differential ex-
pression of GC-responsive genes. Significance was
accepted at a p-value < 0.05.Additional files
Additional file 1: Table S1. list of all 1183 GBS.
Additional file 2: Table S2. GO PC12 unique GBS.
Additional file 3: Table S3. GO GBS with and without GRE.
Additional file 4: Table S4. mRNA primer sequences.
Additional file 5: Table S5. ChIP primer sequences.
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